Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basket of Baskets
2017-005108-89Phase 2Active
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of futibatinib, amivantamab, atezolizumab in Non-hematologic malignancy, advanced nonhematological malignancy, cancer, sponsored by Vall d'Hebron Institute of Oncology. Started Jun 2018; status: active.
02
Drugs
futibatinibamivantamabatezolizumab
03
Conditions
Non-hematologic malignancyadvanced nonhematological malignancycancer
Beyond the preview
Go deeper on 2017-005108-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005108-89.